Antimicrobial resistance profi les and oxacillinase genes in carbapenem-resistant Acinetobacter baumannii isolated from hospitalized patients in Santa Catarina, Brazil

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 48, Issue 6, 2015, Pages 699-705

  Cortivo, Giselle Dall ^a   Gutberlet, Andréia ^b   Ferreira, Jéssica Augustini ^b   Ferreira, Leslie Ecker ^b   Deglmann, Roseneide Campos ^b   Westphal, Glauco Adrieno ^b   de França, Paulo Henrique Condeixa ^b  

^a Hospital Regional Hans Dieter Schmidt   (Brazil)

^b UNIVERSITY OF JOINVILLE REGION   (Brazil)

Author keywords

Acinetobacter; Carbapenem resistance; Nosocomial infection; Oxacillinases

Indexed keywords

AMIKACIN; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULFAMETHOXAZOLE; SULTAMICILLIN; TIGECYCLINE; TRIMETHOPRIM; ANTIINFECTIVE AGENT; BETA LACTAMASE; CARBAPENEM DERIVATIVE; OXACILLINASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BRAZIL; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; DNA EXTRACTION; GENE; GENETIC ANALYSIS; HOSPITAL INFECTION; HOSPITAL PATIENT; LUNG LAVAGE; MINIMUM INHIBITORY CONCENTRATION; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; OXACILLINASE GENE; PREVALENCE; SEQUENCE ANALYSIS; WOUND FLUID; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; CROSS INFECTION; DISK DIFFUSION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GENOTYPE; HUMAN; MICROBIOLOGY; PHENOTYPE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BRAZIL; CARBAPENEMS; CROSS INFECTION; DISK DIFFUSION ANTIMICROBIAL TESTS; GENOTYPE; HUMANS; MULTIPLEX POLYMERASE CHAIN REACTION; PHENOTYPE;

EID: 84951185962     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/0037-8682-0233-2015     Document Type: Article

References (28)

1. El-Ageery SM, Abo-Shadi MA, Alghaithy AA, Ahmad MA, Alsharih NH, Alharbi SA. Epidemiological investigation of nosocomial infection with multidrug-resistant Acinetobacter baumannii. Eur Rev Med Pharmacol Sci 2012; 16: 1834-1839.
2. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. Emergence and widespread dissemination of OXA-23,-24/40 and-58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J Antimicrob Chemother 2009; 6: 55-59.
3. Sydnor ER, Perl TM. Hospital epidemiology and infection control in acute-care settings. Clin Microbiol Rev 2011; 24: 141-173.
4. Chang HC, Chen YC, Lin MC, Liu SF, Chung, YH, Su MC, et al. Mortality risk factors in patients with Acinetobacter baumannii ventilator: associated pneumonia. J Formos Med Assoc 2011; 110: 564-571.
5. Al-Johani SM, Akhter J, Balkhy H, El-Saed A, Younan M, Memish Z. Prevalence of antimicrobial resistance among gram-negative isolates in an adult intensive care unit at a tertiary care center in Saudi Arabia. Ann Saudi Med 2010; 30: 364-369.
6. Higgins PG, Pérez-Llarena FJ, Zander E, Fernández A, Bou G, Seifert H. OXA-235, a novel class D β-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother 2013; 57: 2121-2126.
7. Opazo A, Domínguez M, Bello H, Amyes SG, González-Rocha G. OXA-type carbapenemases in Acinetobacter baumannii in South America. J Infect Dev Ctries 2012; 6: 311-316.
8. Zander E, Bonnin RA, Seifert H, Higgins PG. Characterization of blaOXA-143 variants in Acinetobacter baumannii and Acinetobacter pittii. Antimicrob Agents Chemother 2014; 58: 2704-2708.
9. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-140.
10. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 20th informational supplement. CLSI; 2013. (Accessed 2015 June 4) Available at: http://www. clsi. org/
11. The Medical Letter on Drugs and therapeutics. Tigecycline (Tygacil). Med Lett Drugs Ther 2005; 47: 73-74.
12. Vaneechoutte M, Dijkshoorn L, Tjernberg I, Elaichouni A, de-Vos P, Claeys G, et al. Identification of Acinetobacter genomic species by amplified ribossomal DNA restriction analysis. J Clin Microbiol 1995; 33: 11-15.
13. Bartual SG, Seifert H, Hippler C, Luzon MA, Wisplinghoff H, Rodríguez-Valera F. Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii. J Clin Microbiol 2005; 43: 4382-4390.
14. Higgins PG, Lehmann M, Seifert H. Inclusion of OXA-143 primers in a multiplex polymerase chain reaction (PCR) for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antibicrob Agents 2010; 35: 305.
15. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 2006; 27: 3513.
16. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumanii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-582.
17. Levin AS, Mendes CM, Sinto SI, Sader HS, Scarpitta CR, Rodrigues E, et al. An outbreak of multiresistant Acinetobacter baumannii in a university hospital in São Paulo, Brazil. Infect Control Hosp Epidemiol 1996; 17: 366-368.
18. Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis 2010; 16: 35-40.
19. Carvalho KR, Carvalho-Assef APD, Peirano G, Santos LCG, Pereira MJF, Asensi MD. Dissemination of multidrug-resistant Acinetobacter baumannii genotypes carrying blaOXA-23 collected from hospitals in Rio de Janeiro, Brazil. Int J Antimicrob Agents 2009; 34: 25-28.
20. Cieslinski JM, Arend L, Tuon FF, Silva EP, Ekermann RG, Dalla-Costa LM, et al. Molecular epidemiology characterization of OXA-23 carbapenemase-producing Acinetobacter baumannii isolated from 8 Brazilian hospitals using repetitive sequence-based PCR. Diagn Microbiol Infect Dis 2013; 77: 337-340.
21. Runnegar N, Sidjabat H, Goh HM, Nimmo GR, Schembri MA, Paterson DL. Molecular epidemiology of multidrug-resistant Acinetobacter baumannii in a single institution over a 10-year period. J Clin Microbiol 2010; 48: 4051-4056.
22. Mostachio AK, Levin AS, Rizek C, Rossi F, Zerbini J, Costa SF. High prevalence of OXA-143 and alteration of outer membrane proteins in carbapenem-resistant Acinetobacter spp. isolates in Brazil. Int J Antimicrob Agents 2012; 39: 396-401.
23. Pillonetto M, Arend L, Vespero EC, Pelisson M, Chagas TP, Carvalho-Assef AP, et al. First report of NDM-1-producing Acinetobacter baumannii sequence type 25 in Brazil. Antimicrob Agents Chemother 2014; 58: 7592-7594.
24. Fu Y, Zhou J, Zhou H, Yang Q, Wei Z, Yu Y, et al. Wide dissemination of OXA-23 producing carbapenem-resistant Acinetobacter baumannii clonal complex 22 in multiple cities of China. J Antimicrob Chemother 2010; 65: 644-650.
25. Ruiz M, Marti S, Fernandez-Cuenca F, Pascual A, Vila J. High prevalence of carbapenem-hydrolysing oxacilinases in epidemiologically related and unrelated Acinetobacter baumannii clinical isolates in Spain. Clin Microbiol Infect 2007; 13: 1198.
26. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 3471-3484.
27. Hernández-Torres A, García-Vázquez E, Gómez J, Canteras M, Ruiz J, Fernández-Rufete A, et al. Carbapenem and multidrug-resistant Acinetobacter baumannii colonisation/infection: epidemiology and factors associated with infection. Med Clin (Barc) 2010; 135: 389-396.
28. Castelo-Branco-Fortaleza CM, Moreira-de-Freitas F, da-Paz-Lauterbach G. Colonization pressure and risk factors for acquisition of imipenemresistant Acinetobacter baumannii in a medical surgical intensive care unit in Brazil. Am J Infect Control 2013; 41: 263-265.